A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed and Refractory Lymphomas
Phase of Trial: Phase I/II
Latest Information Update: 05 Dec 2018
At a glance
- Drugs Mogamulizumab (Primary) ; Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2018 Planned End Date changed from 1 Feb 2022 to 1 Jul 2021.
- 11 Oct 2018 Planned primary completion date changed from 1 Feb 2022 to 1 Jul 2021.
- 11 Oct 2018 Status changed from not yet recruiting to recruiting.